about ~ what this notebook is, and what it isn't
About Wolverine Compound: a plain-drawn digest of the BPC-157 TB-500 record.
An independent editorial project. We summarize published research; we don't treat, prescribe, sell, or supply anything.
What Wolverine Compound is
Wolverine Compound is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157 TB-500 — the two-peptide pairing better known by its research-community nickname, the "Wolverine" blend. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product, and we do not supply either peptide or the blend. Our work is editorial commentary on publicly available science.
The register here is deliberately friendly — a plain-drawn notebook rather than an instrument panel — because the subject is a folk-named gym-community "stack," and a calm, approachable read is the honest way to handle cautionary material. The friendliness is in the drawing; the discipline is in the citations.
Why a 'compound' site is not a pharmacy
The word "compound" in our name is editorial framing. It refers to the chemistry — these are research compounds — and to the regulatory conversation around compounding pharmacies, which we cover on the Wolverine legal status and FDA 503A category page. It is not a claim that this site compounds, dispenses, or sells anything. There is no pharmacy here, no counter, and no order form.
That distinction matters because the blend's most important facts are cautionary: there is no controlled human trial of the combination [8], there is a standing tumor-angiogenesis concern around Thymosin Beta-4 [5], and both constituents are unapproved and WADA-prohibited. A digest can state those things plainly precisely because it has nothing to sell.
How we work
We read the primary literature and recent reviews, pull the specific numbers, and attribute every quantitative claim to a study you can verify in the full reference list. When a finding is preclinical, we label it preclinical. When the human data are thin or absent — as they are for this blend — we say so rather than implying more. And when the regulatory picture is in motion, as it is with the July 2026 advisory-committee review, we report the scheduled facts without guessing the outcome [12].
If you notice an error or a citation that needs correcting, the contact page explains how to reach us.